These documents may include preclinical, clinical and regulatory documents (such as protocols, investigator's brochures, clinical study reports, briefing documents, regulatory responses, Target Product Profiles, regulatory strategy documents, and Integrated Development Plans), global clinical trial applications (IND/CTA documents), and external scientific publications (such as abstracts, posters, manuscripts, and presentations). Through its interconnected pillars-Lilly Ventures, Lilly Gateway Labs, Lilly ExploR&D, and Lilly TuneLab-Catalyze360 strategically removes barriers that traditionally block bold science from becoming life-changing medicines, providing biotechs with flexible combinations of capital, physical lab space, R&D capabilities, AI/ML tools, and decades of enterprise learning.